港股异动 | 医药股多数走强年内多项利好政策陆续出台国谈有望促进创新药长期放量

智通财经2024-10-18

智通财经APP获悉，医药股多数走强，截至发稿，来凯医药-B(02105)涨12.27%，报8.05港元；再鼎医药(09688)涨11.72%，报22.4港元；和誉-B(02256)涨9.6%，报3.88港元；药明合联(02268)涨7.89%，报22.55港元；诺诚健华(09969)涨6.37%，报6.85港元。消息面上，广东省人民政府办公厅近日印发《关于进一步推动广东生物医药产业高质量发展的行动...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2476411142?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-10-18 10:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2476411142","market":"sh","top_or_hot":-1,"title":"港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，医药股多数走强，截至发稿，来凯医药-B(02105)涨12.27%，报8.05港元；再鼎医药(09688)涨11.72%，报22.4港元；和誉-B(02256)涨9.6%，报3.88港元；药明合联(02268)涨7.89%，报22.55港元；诺诚健华(09969)涨6.37%，报6.85港元。消息面上，广东省人民政府办公厅近日印发《关于进一步推动广东生物医药产业高质量发展的行动...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1195742.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-18 10:57 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1195742.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，医药股多数走强，截至发稿，来凯医药-B(02105)涨12.27%，报8.05港元；再鼎医药(09688)涨11.72%，报22.4港元；和誉-B(02256)涨9.6%，报3.88港元；药明合联(02268)涨7.89%，报22.55港元；诺诚健华(09969)涨6.37%，报6.85港元。消息面上，广东省人民政府办公厅近日印发《关于进一步推动广东生物医药产业高质量发展的行动...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1195742.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"159938","symbol_name":"医药","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1195742.html","article_id":"2476411142","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2476411142","pubTimestamp":1729220234,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"光大证券认为，今年以来，针对创新药领域，多项利好政策陆续出台。随着政策落地，创新药发展有望迈入快车道。国投证券指出，国谈进入常态化阶段，创新药长期放量可期。2024年医保谈判预计将于近期开启，多个国产创新药将参加本年度医保谈判。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"159938":"医药","159992":"创新药","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK1161":"生物科技","BK1588":"回港中概股","06978":"永泰生物-B","09688":"再鼎医药","02268":"药明合联","02105":"来凯医药-B","BK1574":"生物医药B类股","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","09939":"开拓药业-B","BK1515":"抗疫概念","BK1141":"生命科学工具和服务","09969":"诺诚健华","02256":"和誉-B"},"translate_title":"Hong Kong stocks have changed, most pharmaceutical stocks have strengthened, and a number of favorable policies have been introduced one after another during the year. National talks are expected to promote the long-term increase in the volume of innovative drugs","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"159992":1,"06978":1,"09939":1,"02105":0.9,"02256":0.9,"02268":0.9,"09688":0.9,"09969":0.9},"content_text":"智通财经APP获悉，医药股多数走强，截至发稿，来凯医药-B(02105)涨12.27%，报8.05港元；再鼎医药(09688)涨11.72%，报22.4港元；和誉-B(02256)涨9.6%，报3.88港元；药明合联(02268)涨7.89%，报22.55港元；诺诚健华(09969)涨6.37%，报6.85港元。消息面上，广东省人民政府办公厅近日印发《关于进一步推动广东生物医药产业高质量发展的行动方案》，进一步推动广东省生物医药产业集聚成势，力争到2027年，当地生物医药与健康产业集群规模超万亿元，规上医药工业规模超5000亿元。光大证券认为，今年以来，针对创新药领域，多项利好政策陆续出台。新政策分别从支付端、融资端、审评端、考核端等多个维度全链条助推创新药的商业化以及研发，彰显部分省份对创新药物全链条支持的高度重视。随着政策落地，创新药发展有望迈入快车道。国投证券指出，国谈进入常态化阶段，创新药长期放量可期。2024年医保谈判预计将于近期开启，多个国产创新药将参加本年度医保谈判。国家医保局公布《2024年国家基本医疗保险、工伤保险和生育保险药品目录调整工作方案》，根据调整工作方案，2024年国家药品目录调整工作流程分为准备、申报、专家评审、谈判/竞价阶段、公布结果，共5个阶段；本次医保谈判中多个药品进行首次谈判、新增适应症谈判、到期续约谈判等，国产创新药医保谈判已经进入常态化阶段。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.4","shortVersion":"4.29.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2476411142"}

港股异动 | 医药股多数走强 年内多项利好政策陆续出台 国谈有望促进创新药长期放量

精彩评论

港股异动 | 医药股多数走强年内多项利好政策陆续出台国谈有望促进创新药长期放量